loading   Loading page...

Välkommen hit.
Om du ser denna ruta är detta projekt arkiverat.
Varmt välkommen över till våra aktiva sidor.


Cancer Crosslinks 2016
Lund - Sweden


Welcome to the fourth Cancer Crosslink Sweden

October 19, 2016, at Medicon Village, Lund

By bringing together researchers from healthcare providers, academia, and industry with representatives from regulatory units in a one-day meeting, we want to start an interdisciplinary discussion that could lead to new partnerships to develop the area of ​​Precision Medicine and Immuno-oncology.


The concept of Cancer Crosslink meetings was established in Oslo, Norway, nine years ago when Oslo Cancer Cluster www.oslocancercluster.no in collaboration with Bristol-Myers Squibb arranged the first Cancer Crosslink meeting.
Since then, initiatives to Crosslink meetings has been taken both in Sweden and Finland.


Main sponsors

Also supported by

Sessions - Program - Speakers


  • SESSION I – Immuno-oncology in clinical practice
  • SESSION II – Next step in Personalized Healthcare
  • SESSION III – Clinical effectiveness – How to meet the future

Download 2016 Program Draft
(PDF, 285kb)


Confirmed Speakers

Key note I:  Prof. Gordon J. Freeman, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA

Key note II: Dr. Robert Miller, American Society of Clinical Oncology, Alexandria, USA

Prof. Gunilla Enblad, Uppsala University, Uppsala, Sweden

Dr. Robert Comis,  ECOG-ACRIN Cancer Research Group, Philadelphia, USA

Prof. Susan Lutgendorf, University of Iowa, Iowa, USA

Prof. Henrik Grönberg, Karolinska Institute, Stockholm, Sweden

Prof. Peter Lichter, German Cancer Research Center, DKFZ, Heidelberg, German

Dr. Giuseppe Masucci, Karolinska Institute, Stockholm, Sweden

Dr. Thorbald van Hall, Leiden University Medical centre, Netherlands

Dr. Marco Donia, Herlev Hospital, University of Copenhagen, Denmark


Click on the relevant speaker's name to learn more about the speaker. (opens in a new window)


Practical information

The conference will take place at the Medicon Village

Address: Sheelevägen 2, Lund

Map and transport/parking information, Medicon Village:

Click here to open PDF with transport and parking information.


For more information, please contact research coordinator Ulrika Axelsson:

+46 46 222 86 15

For information about Lund city and
book your accomodation:


The hotel closest to the conference is Hotel Elite Ideon.


At Medicon Village the entire value chain, from researchers to innovators and businessmen, will work together under a single flag to create value for people’s health and wellbeing.
Different skills and knowledge brought together through collaboration create growth, and good ideas that are born out of everyday meetings can make the difference for tomorrow’s patients. 


Lund is located in the southern part of Sweden, also known as the County of Skåne. It is a vibrant research area hosting one of the oldest and the largest university in Scandinavia - Lund University.
The region consist of an internationally renowned life science cluster Medicon Valley with more than 350 Research and Development companies in the fields of biotechnology, pharmaceuticals and medical technology.
The collaboration between the academy, the hospitals and the industry has fostered innovative and dynamic research projects in the fields of cancer, diabetes, inflammation and CNS among others.


CREATE Health:

CREATE Health is a Strategic Centre for Translational Cancer Research at Lund University (www.createhealth.lth.se).
By integrating clinicians and researchers from Lund University Hospital with researchers from the Faculties of Medicine, Natural Sciences and Engineering, using a superbly equipped and integrated “omics” platforms, concentrated in a single area, a centre unique in its kind has been created.
The vision of CREATE Health is to use an integrative approach to develop novel diagnostics and therapeutics, based on identified markers and molecular signatures and to create a substantial social impact for the patient, through direct application of research for selection of an optimal, individually-based, cancer treatment, i.e. personalized medicine.